Renalytix Business Summary

Renalytix plc operates as an artificial intelligence-enabled in vitro diagnostics company specializing in the "bioprognosis" of kidney health. The company generates revenue primarily through transaction-based fees from its flagship KidneyIntelX.dkd test, which is the only FDA-approved and Medicare-reimbursed prognostic tool for early-stage chronic kidney disease (CKD) risk assessment, priced at $950 per reportable result. Its business is divided into two primary segments: clinical diagnostic testing, which leverages integrations with major U.S. healthcare provider electronic medical record (EMR) systems, and pharmaceutical services, which provides data-driven insights to global drug developers. Direct competitors in the digital health and renal diagnostic space include lifespin, Kahun, and Avellino; however, Renalytix maintains a dominant market position as the sole provider of a regulatory-cleared prognostic platform specifically indicated for type 2 diabetes patients with early-stage CKD. The company was co-founded by CEO James McCullough and CTO Fergus Fleming in collaboration with faculty from the Icahn School of Medicine at Mount Sinai. McCullough brings a deep pedigree in life sciences, having previously served as CEO of Exosome Diagnostics, while Fleming offers over 30 years of experience from leadership roles at Baxter Healthcare and Boston Scientific. The executive team is further strengthened by Executive Chairman Julian Baines, the former CEO of EKF Diagnostics and BBI Holdings, and Interim CFO Joel Jung. Notable institutional backing and strategic influence come from the Icahn School of Medicine at Mount Sinai, which remains a significant equity owner, and Harwood Capital, led by board member Christopher Mills. Additionally, the company recently entered a high-profile strategic collaboration with Tempus AI to accelerate the commercial adoption of its technology across a vast network of U.S. healthcare institutions.